Multiple Myeloma

Celgene's Multiple Myeloma Powerhouse
Celgene's Multiple Myeloma Powerhouse
Motley Fool
Multiple Myeloma
Celgene
Thalomid
Revlimid
Pomalyst
Flag link:
Celgene spends $100M for option to buy myeloma drug developer Acetylon
Celgene spends $100M for option to buy myeloma drug developer Acetylon
Fierce Biotech
Celgene
Multiple Myeloma
M&A
Acetylon
Flag link:
Celgene's Revlimid improves survival in blood cancer patients
Celgene's Revlimid improves survival in blood cancer patients
Reuters
Celgene
Revlimid
Multiple Myeloma
Flag link:
Coronado Biosciences Reuniting Old Friends
Coronado Biosciences Reuniting Old Friends
Seeking Alpha
Coronado Biosciences
CNDO-201
CNDO-109
Crohn's Disease
Multiple Myeloma
acute myeloid leukemia
Flag link:
MorphoSys Rises on $818 Million Drug Alliance
MorphoSys Rises on $818 Million Drug Alliance
Bloomberg
MorphoSys
MOR202
Celgene
Multiple Myeloma
Flag link:
Johnson & Johnson's Potential Blockbuster For Multiple Myeloma And Its Competitors
Johnson & Johnson's Potential Blockbuster For Multiple Myeloma And Its Competitors
Seeking Alpha
JNJ
Multiple Myeloma
daratumumab
Genmab
Flag link:
Threshold Pharmaceuticals Announces Data From Two Ongoing Phase 1/2 Trials of TH-302 at the 2013 ASCO Annual Meeting
Threshold Pharmaceuticals Announces Data From Two Ongoing Phase 1/2 Trials of TH-302 at the 2013 ASCO Annual Meeting
Yahoo/MarketWire
Threshold Pharmaceuticals
TH-302
Multiple Myeloma
gastrointestinal stromal tumors
renal cell carcinoma
kidney cancer
Flag link:
Genmab Rises After FDA Grants Breakthrough Status to Cancer Drug
Genmab Rises After FDA Grants Breakthrough Status to Cancer Drug
Bloomberg
Genmab
FDA
JNJ
daratumumab
Multiple Myeloma
Flag link:
Celgene's Star Drug Revlimid And Its Competitors
Celgene's Star Drug Revlimid And Its Competitors
Seeking Alpha
Celgene
Revlimid
Multiple Myeloma
JNJ
Velcade
AbbVie
Bristol-Myers Squibb
elotuzumab
Flag link:
Genmab Rises as Nordea Says Bet on Cancer Drug: Copenhagen Mover
Genmab Rises as Nordea Says Bet on Cancer Drug: Copenhagen Mover
Bloomberg
Genmab
JNJ
daratumumab
Multiple Myeloma
Flag link:
Aeterna Zentaris to Discontinue Phase 3 Trial in Multiple Myeloma with Perifosine Following Data Safety Monitoring Board Recommendation
Aeterna Zentaris to Discontinue Phase 3 Trial in Multiple Myeloma with Perifosine Following Data Safety Monitoring Board Recommendation
Yahoo
Aeterna Zentaris
Multiple Myeloma
perifosine
Flag link:
Celgene And The Race To Cure Multiple Myeloma
Celgene And The Race To Cure Multiple Myeloma
Seeking Alpha
Celgene
Multiple Myeloma
Pomalyst
Flag link:
Can Johnson & Johnson Hold Its Ground in the Multiple Myeloma Market?
Can Johnson & Johnson Hold Its Ground in the Multiple Myeloma Market?
Motley Fool
JNJ
Multiple Myeloma
Velcade
Celgene
Revlimid
AbbVie
ONYX Pharmaceuticals
Bristol-Myers Squibb
Flag link:
Celgene Gets OK to Sell Blood Cancer Drug
Celgene Gets OK to Sell Blood Cancer Drug
Minyanville
Celgene
Pomalyst
Multiple Myeloma
Flag link:
Still Revving Up With Revlimid
Still Revving Up With Revlimid
Motley Fool
Revlimid
myelodysplastic syndrome
Multiple Myeloma
Celgene
Flag link:
FDA approves generic version of cancer drug Doxil
FDA approves generic version of cancer drug Doxil
Reuters
FDA
generics
Doxil
Sun Pharma
JNJ
ovarian cancer
Multiple Myeloma
Flag link:
Watson challenges patent on cancer drug Velcade
Watson challenges patent on cancer drug Velcade
Yahoo/AP
Watson Pharmaceuticals
Velcade
Millennium
Multiple Myeloma
Flag link:
Celgene Investors: What to Watch
Celgene Investors: What to Watch
Motley Fool
Celgene
pomalidomide
Multiple Myeloma
Flag link:
10 Drugs Approved by the FDA in 2012 to Be Thankful For
10 Drugs Approved by the FDA in 2012 to Be Thankful For
Motley Fool
Xtandi
Medivation
prostate cancer
Stribild
Gilead Sciences
HIV
Belviq
Arena Pharmaceuticals
obesity
weight loss
Qsymia
Vivus
Kyprolis
ONYX Pharmaceuticals
Multiple Myeloma
Omontys
Affymax
anemia
Linzess
irritable bowel syndrome
Ironwood Pharmaceuticals
Bosulif
chronic myeloid leukemia
Pfizer
Amyvid
Alzheimer's disease
Eli Lilly
Eylea
macular degeneration
Regeneron
Flag link:
Celgene's Momentum Continues
Celgene's Momentum Continues
Motley Fool
Celgene
pomalidomide
Multiple Myeloma
Flag link:

Pages